new lung cancer drug opdivo fda approval

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
new lung cancer drug opdivo fda approval	1.41	0.4	350	15	40
new	1.83	0.3	5155	14	3
lung	0.17	0.8	3510	50	4
cancer	1.98	0.2	4829	5	6
drug	1.71	1	7627	17	4
opdivo	0.53	0.6	1751	57	6
fda	0.9	0.3	4738	43	3
approval	0.46	0.8	5340	6	8

Keyword	CPC	PCC	Volume	Score
new lung cancer drug opdivo fda approval	1.8	0.1	2408	19
new lung cancer drug opdivo reviews	0.87	0.7	3825	87
new lung cancer drug opdivo clinical trials	0.53	0.7	5807	68
new lung cancer drug opdivo manufacturer	1.67	0.8	623	8
new lung cancer drug opdivo results	0.91	0.4	1898	53
new lung cancer drug opdivo nivolumab	1.04	0.7	3513	66
opdivo small cell lung cancer fda	1.69	0.2	4945	72
lung cancer drug opdivo	1.75	0.6	3433	13
new lung cancer drug opdivo dosage	1.53	0.7	204	88
new lung cancer drug opdivo success rate	0.98	0.5	696	12
opdivo yervoy lung cancer fda approval	0.49	0.8	2328	64
new lung cancer drug opdivo survival rates	1.23	0.4	5162	37
opdivo lung cancer treatment	1.81	0.3	56	18
opdivo for lung cancer	1.68	0.2	7136	11
opdivo for small cell lung cancer treatment	0.67	0.8	1937	7
opdivo immunotherapy for lung cancer cost	0.59	0.9	9473	8
opdivo for small cell lung cancer	1.82	0.3	4685	7
opdivo immunotherapy for lung cancer nhs	0.61	0.6	5877	5
opdivo immunotherapy for lung cancer reviews	0.32	0.6	6359	98
opdivo immunotherapy for lung cancer	1.48	0.8	6230	47
clinical trials opdivo small cell lung cancer	1.01	0.7	4487	95